• $585.4M
    Market Cap
  • N/A
    1-Year Change
  • Biotechnology
    Industry
Annual
Quarterly
12/31/2025
Income Statement
Total Operating Revenue
23,426
N/A
Cost of Revenue
7,965
N/A
Gross Profit
15,461
N/A
Sales and Marketing Expense
6.9M
N/A
Research and Development Expense
-10.3M
N/A
Depreciation and Amortization Expense
N/A
N/A
Total Operating Expenses
46.9M
N/A
Operating Profit
N/A
N/A
Interest Income
N/A
N/A
Interest Expense
N/A
N/A
Interest Income and Expense and Net
0
N/A
Total Nonoperating Income and Expense
N/A
N/A
Income before Taxes
N/A
N/A
Income Taxes
-392,603
N/A
Extraordinary Items
N/A
N/A
Net Income
N/A
N/A
Net Income from Continuing Operations Applicable to Common
N/A
N/A
Basic EPS and Net Income
-4.60
N/A
Diluted EPS and Net Income
-4.60
N/A
Basic Weighted Average Shares
N/A
N/A
Diluted Weighted Average Shares
N/A
N/A
Balance Sheet
Cash and Cash Equivalents
101,000
N/A
Short-Term Investments
N/A
N/A
Cash and Cash Equivalents and Short-Term Investments
101,000
N/A
Total Current Assets
101,000
N/A
Accumulated Depreciation
N/A
N/A
Property and Plant and Equipment and Net
741,098
N/A
Total Long-Term Assets
77.9M
N/A
Total Assets
101,000
N/A
Income Taxes Payable
N/A
N/A
Total Short-Term Debt
N/A
N/A
Total Current Liabilities
6.6M
N/A
Total Long-Term Debt
N/A
N/A
Total Long-Term Liabilities
90.0M
N/A
Total Liabilities
27,856
N/A
Retained Earnings
-26,856
N/A
Total Stockholders Equity
73,144
N/A
Total Shares Outstanding
N/A
N/A
Cash Flow
Cash from Operating Activities
-9.9M
N/A
Capital Expenditures
N/A
N/A
Cash from Investing Activities
-437,176
N/A
Dividends Paid
N/A
N/A
Cash from Financing Activities
6.6M
N/A
Financials Ratio
Gross Margin
N/A
N/A
Operating Margin
N/A
N/A
Return on Assets
N/A
N/A
Return on Equity
N/A
N/A
Revenue Growth
N/A
N/A
Current Ratio
N/A
N/A
Cash Ratio
N/A
N/A
Debt-to-Equity Ratio
N/A
N/A
Debt-to-Assets Ratio
N/A
N/A

Earnings & Revenue History

Debt-to-Assets

Cash Flow